Kristie L. Kahl

In its Speaking Out video series, on behalf of Aim at Melanoma, CURE ® spoke with Dr. Sunandana Chandra about emerging therapies in melanoma.

On behalf of AiM at Melanoma, Drs. Jeffrey Farma and Sunandana Chandra discuss current and future treatment options for melanoma, including a rare subtype.

Results from a recent study strongly support a treatment regimen of Darzalex with Revlimid and dexamethasone as a new standard of care for patients with transplant-ineligible newly diagnosed multiple myeloma.

On behalf of the Head and Neck Cancer Alliance, Dr. Michael Moore spoke with CURE® about emerging therapies that potentially offer exciting new options for the future.

After long-term follow-up, the CAR-T cell therapy still boosted survival outcomes in patients with relapsed/refractory multiple myeloma, regardless of the number of prior lines of therapy received.

In patients with metastatic renal cell carcinoma whose disease failed to respond to two prior therapies, Fotivda, compared with Nexavar, contributed to a duration of response of 20.3 months versus 9 months.

Treatment with chemotherapy following the standard chemoradiation treatment failed to improve multiple survival outcomes in women with locally advanced cervical cancer.

Clinical trials are often the key to advancements in treating ovarian cancer. As part of its “Speaking Out” video series, CURE® spoke with Dr. Debra Richardson about what patients should know about joining a trial.

As part of the “Speaking Out” video series, CURE® spoke with Dr. Laura M. Kulik about the basics of liver cancer, highlighting the need for a multidisciplinary approach to care.

As part of its “Speaking Out” video series, CURE® spoke with Katie Brown from LUNGevity about challenges that have arisen from the COVID-19 pandemic — including delays in screening — and resources to help patients through these trying times.

In partnership with CURE®, Bonnie J. Addario and the GO2 Foundation for Lung Cancer will release “The Living Room: A Lung Cancer Community of Courage,” a collection of stories from patients, caregivers and survivors taking a personal approach to cancer care.

On Feb. 18, CURE hosted a webinar focused on educating patients on biomarker testing. Here, we highlight key takeaways from our panelists.

On behalf of the National Ovarian Cancer Coalition, CURE spoke with Dr. Debra Richardson, from Stevenson Cancer Center, about the basics of ovarian cancer and its treatments, clinical trials and psychosocial effects.

CURE spoke with Dr. Marty T. Sellers and Dr. Laura M. Kulik, on behalf of the Blue Faery, about liver cancer and disease – its treatments, causes and areas outside of therapy.

CURE spoke with Dr. Eric Jonasch about the National Comprehensive Cancer Network’s Category 1 recommendation for the combination use of Lenvima plus Keytruda for the treatment of front-line renal cell carcinoma. In particular, how it can impact a patient’s treatment journey.

CURE spoke with a cancer rights attorney about what financial toxicity is and ways to address this burden before assistance is needed.

Dr. John Marshall and his wife, Liza, look back on the trials and tribulations of Liza’s triple-negative breast cancer diagnosis – from the perspective of a patient and her husband, the caregiver and oncologist.

“This approval is an important advancement for patients whose disease has relapsed and reinforces the potential for Sarclisa to become a standard of care in relapsed or refractory multiple myeloma,” said Dr. Thomas G. Martin.

CURE® spoke with a cancer rights attorney about employment rights and how patients and their caregivers can learn more to ensure they are being protected.

The agency granted approval to the revised label of Vyxeos to now include treatment for newly diagnosed therapy-related acute myeloid leukemia or disease with myelodysplasia-related changes in pediatric patients aged 1 and older.